Table 1.
Participant characteristics for our cohort.
| Total Cohort N=108† |
|
|---|---|
| Age (years) | |
| Median (25th, 75th) | 49 (44, 55) |
| Min, Max | 28, 70 |
| Male | 100 (92.6%) |
| Race | n=107 |
| Non-Hispanic White | 34 (31.8%) |
| Non-Hispanic Black | 55 (51.4%) |
| Other | 18 (16.8%) |
| Alcohol risk | |
| None or minimal | 60 (55.6%) |
| Low-risk | 34 (31.5%) |
| Heavy | 14 (13.0%) |
| Body mass index (kg/m2) | n=104 |
| Median (25th, 75th) | 26.3 (22.4, 30.6) |
| Min, Max | 16.6, 48.5 |
| ALT (IU/L) | n=106 |
| Median (25th, 75th) | 27 (19, 39) |
| Min, Max | 8, 223 |
| ALT (by standard ULN‡) | n=106 |
| ≤1 | 57 (53.8%) |
| >1-≤2 | 35 (33.0%) |
| >2 | 14 (13.2%) |
| AST (IU/L) | n=106 |
| Median (25th, 75th) | 28 (23, 39) |
| Min, Max | 13, 202 |
| AST (by lab-specific ULN§) | n=106 |
| ≤1 | 82 (77.4%) |
| >1-≤2 | 21 (19.8%) |
| >2 | 3 (2.8%) |
| Platelets (x103/mm3) | n=106 |
| Median (25th, 75th) | 199 (174, 234) |
| Min, Max | 84, 344 |
| Anti-HCV positive | 6 (5.6%) |
| Anti-HDV positive | 4 (3.7%) |
| Sexually transmitted | n=99 |
| 94 (94.9%) | |
| Estimated duration of HIV Infection (years) | n=97 |
| Median (25th, 75th) | 20 (10, 25) |
| Min, Max | 1, 4 |
| HIV RNA copies/ml | n=98 |
| 0 - <20 | 76 (77.6%) |
| 20 - <100 | 8 (8.2%) |
| 100 - <10000 | 11 (11.2%) |
| ≥ 10000 | 3 (3.1%) |
| CD4 (cells/mm3) | n=99 |
| Median (25th, 75th) | 567 (366, 718) |
| Min, Max | 38, 1395 |
| HIV stage | n=80 |
| 1 (CD4 ≥500 cells/mm3) | 61 (76.3%) |
| 2 (CD4 350-499 cells/mm3) | 10 (12.5%) |
| 3 (CD4 200-349 cells/mm3) | 5 (6.3%) |
| 4 (CD4 <200 cells/mm3) | 4 (5.0%) |
| Estimated duration of HBV Infection (years) | n=82 |
| Median (25th, 75th) | 13.5 (8.0, 22.0) |
| Min, Max | 1.0, 52.0 |
| HBeAg Positive | 61 (56.5%) |
| Quantitative HBeAg (IU/mL), among HBeAg positive | n=60 |
| Median (25th, 75th) | 15.0 (1.9, 198.9) |
| Min, Max | 0.5, 2058.1 |
| Quantitative HBsAg (IU/mL) | n=106¶ |
| Median (25th, 75th) | 1440.5 (307.1, 7755.0) |
| Min, Max | BLD#, 647460.0 |
| HBV DNA level (IU/mL) | |
| <1000 | 89 (82.4%) |
| 1000-<20000 | 7 (6.5%) |
| ≥20000 | 12 (11.1%) |
| Currently on cART treatment | 107 (99.1%) |
| Tenofovir, alone or in combination | 92 (85.2%) |
| Emtricitabine | 80 (74.8%) |
| Lamivudine, alone or combination | 19 (17.6%) |
| Entecavir | 16 (14.8%) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; cART, combination antiretroviral therapy; CD, cluster of differentiation, DNA, deoxyribonucleic acid; HBeAg, quantitative e antigen; HBsAg, quantitative s antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis Delta virus; HIV, human immunodeficiency virus; RNA ribonucleic acid.
Unless otherwise specificied due to missing data.
Upper limit of normal (ULN) ALT ≤30 IU/L in men, ALT ≤19 U/L in women
Upper limit of normal (ULN) AST by each local laboratory
Two participants who were HBsAg positive via local laboratory did not have HBsAg measured by central laboratory.
Four participants who were HBsAg positive via local laboratory had HBsAg below level of detection by central laboratory.